Sanila Sarkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sanila Sarkar has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Lea M. Stitzlein
Division of Pediatrics The University of Texas MD Anderson Cancer Center Houston Texas USA
2 shared publicationsRamia Zakhour
Division of Infectious Diseases McGovern Medical School at UT Health Houston, and Children's Memorial Hermann Hospital Houston Texas USA
2 shared publicationsShehla Razvi
Division of Pediatrics The University of Texas MD Anderson Cancer Center Houston Texas USA
2 shared publicationsEmily Rav
Division of Pediatrics The University of Texas MD Anderson Cancer Center Houston Texas USA
1 shared publication- Emily Rav
Department of Pediatrics The University of Texas MD Anderson Cancer Center Houston Texas USA
1 shared publication - Joya Chandra
Department of Pediatrics Research, University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication
Latest Publications
- Open Access
- 28 February 2024
- Published by Wiley in Cancer Reports
- Vol. 7 (3) , e1982
Case series: Stenotrophomonas maltophilia in pediatric oncology patients
Background: Stenotrophomonas maltophilia is a bacterial pathogen that can be fatal in hospitalized and immunocompromised patients with mortality as high as 69%. Pediatric cancer patients often have risk factors that are common for this infection, making them particularly susceptible. Managing S. maltophilia is especially challenging as it has inherent resistance to several antibiotics. Furthermore, soft tissue infections in neutropenic patients may deviate from the typical clinical presentation of S. maltophilia.Case Details: This case series describes an in‐depth examination of three cases involving immunocompromised pediatric patients with S. maltophilia infections. Each case exhibited a distinct clinical presentation, encompassing infection of the blood, lung, and skin, which highlights the variability in which S. maltophilia manifests in immunocompromised pediatric patients. These patients were treated at MD Anderson Cancer Center (MDACC) from 2020 to 2023, unfortunately resulting in fatality.Conclusions: The study aims to provide valuable insights and guidance for the management of patients with S. maltophilia infections. Emphasizing a heightened clinical suspicion will potentially lead to early initiation of directed therapy against S. maltophilia. Timely intervention may play a pivotal role in improving patient outcomes and reduce further burden to the healthcare system.
- 28 February 2024
- Published by Wiley in Cancer Reports
- Vol. 7 (3) , e1982
Open AccessCase series: Stenotrophomonas maltophilia in pediatric oncology patients
Background: Stenotrophomonas maltophilia is a bacterial pathogen that can be fatal in hospitalized and immunocompromised patients with mortality as high as 69%. Pediatric cancer patients often have risk factors that are common for this infection, making them particularly susceptible. Managing S. maltophilia is especially challenging as it has inherent resistance to several antibiotics. Furthermore, soft tissue infections in neutropenic patients may deviate from the typical clinical presentation of S. maltophilia.Case Details: This case series describes an in‐depth examination of three cases involving immunocompromised pediatric patients with S. maltophilia infections. Each case exhibited a distinct clinical presentation, encompassing infection of the blood, lung, and skin, which highlights the variability in which S. maltophilia manifests in immunocompromised pediatric patients. These patients were treated at MD Anderson Cancer Center (MDACC) from 2020 to 2023, unfortunately resulting in fatality.Conclusions: The study aims to provide valuable insights and guidance for the management of patients with S. maltophilia infections. Emphasizing a heightened clinical suspicion will potentially lead to early initiation of directed therapy against S. maltophilia. Timely intervention may play a pivotal role in improving patient outcomes and reduce further burden to the healthcare system.
- Open Access
- 1 February 2024
- Published by AME Publishing Company in Pediatric Medicine
- Vol. 7, 3
Impact of electronic cigarettes on pediatric, adolescent and young adult leukemia patients
Electronic cigarettes, which deliver an aerosolized, nicotine-containing product upon inhalation, are a public health issue that continue to gain popularity among adolescents and young adults in the United States. Use of electronic cigarettes is wide, and extends to pediatric patients with multiple comorbidities, including childhood cancer, leaving them vulnerable to further negative health outcomes. Acute leukemias are the most common type of cancer in pediatric populations, and treatment outcomes for these patients are improving; consequently, there is an increased emphasis on the effect of behavioral lifestyle factors on quality of life in survivorship. The rate of electronic cigarette use is higher among pediatric patients with a history of cancer than those without a history of cancer. Because electronic cigarettes are relatively new, much about their acute and long-term consequences remains unknown, as is their effect on therapy outcomes and long-term survivorship. This review article summarizes current knowledge about electronic cigarettes, including their composition and the trends in use among pediatric patients. Furthermore, this review provides a comprehensive description of the impact electronic cigarettes have on leukemia development, treatment and survivorship and highlights gaps in knowledge that will be necessary for developing recommendations, management strategies, and tailored treatments for pediatric leukemia patients and survivors who use these nicotine products.
- 1 February 2024
- Published by AME Publishing Company in Pediatric Medicine
- Vol. 7, 3
Open AccessImpact of electronic cigarettes on pediatric, adolescent and young adult leukemia patients
Electronic cigarettes, which deliver an aerosolized, nicotine-containing product upon inhalation, are a public health issue that continue to gain popularity among adolescents and young adults in the United States. Use of electronic cigarettes is wide, and extends to pediatric patients with multiple comorbidities, including childhood cancer, leaving them vulnerable to further negative health outcomes. Acute leukemias are the most common type of cancer in pediatric populations, and treatment outcomes for these patients are improving; consequently, there is an increased emphasis on the effect of behavioral lifestyle factors on quality of life in survivorship. The rate of electronic cigarette use is higher among pediatric patients with a history of cancer than those without a history of cancer. Because electronic cigarettes are relatively new, much about their acute and long-term consequences remains unknown, as is their effect on therapy outcomes and long-term survivorship. This review article summarizes current knowledge about electronic cigarettes, including their composition and the trends in use among pediatric patients. Furthermore, this review provides a comprehensive description of the impact electronic cigarettes have on leukemia development, treatment and survivorship and highlights gaps in knowledge that will be necessary for developing recommendations, management strategies, and tailored treatments for pediatric leukemia patients and survivors who use these nicotine products.
- Open Access
- 19 April 2023
- Published by Wiley
Case Series: Stenotrophomonas maltophilia in Pediatric Oncology Patients
Stenotrophomonas maltophilia is a bacterial pathogen that can be fatal in hospitalized and immunocompromised patients with mortality as high as 69%. Risk factors for infection include those apparent in many pediatric cancer patients. Treatment is challenging as S. maltophilia is resistant to several antibiotics. Furthermore, the presentation of soft tissue infection in neutropenic patients may be atypical. We present three immunocompromised pediatric patients with S. maltophilia infections. All three cases were fatal. We hope our experience at MD Anderson can guide providers to diagnose and properly treat Stenotrophomonas infection, as timely treatment may improve morbidity and mortality.
- 19 April 2023
- Published by Wiley
Open AccessCase Series: Stenotrophomonas maltophilia in Pediatric Oncology Patients
Stenotrophomonas maltophilia is a bacterial pathogen that can be fatal in hospitalized and immunocompromised patients with mortality as high as 69%. Risk factors for infection include those apparent in many pediatric cancer patients. Treatment is challenging as S. maltophilia is resistant to several antibiotics. Furthermore, the presentation of soft tissue infection in neutropenic patients may be atypical. We present three immunocompromised pediatric patients with S. maltophilia infections. All three cases were fatal. We hope our experience at MD Anderson can guide providers to diagnose and properly treat Stenotrophomonas infection, as timely treatment may improve morbidity and mortality.